newsfilter
← Latest News
PR Newswire·

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

GTBPIPHAINKTIPSC
  • GT Biopharma (NASDAQ: GTBP) dosed the first patient in May 2026 for its third clinical candidate, GTB-5550, advancing from a blood cancer focus to solid tumors.
  • The company now operates two simultaneous human trials using its TriKE® platform: GTB-3650 for CD33-expressing blood cancers & GTB-5550 for B7-H3-targeted solid tumors.
  • GTB-5550 is the first TriKE molecule designed as a dual-nanobody construct with subcutaneous dosing capabilities.
  • The GTB-5550 Phase 1 dose-escalation trial prioritizes prostate cancer, with data updates expected in the second half of 2026.
  • GT Biopharma's TriKE platform recruits patient NK cells via a single engineered molecule that targets CD16, sustains cells with IL-15, & binds tumor markers.
  • The platform was licensed from the University of Minnesota, which retains a royalty interest in future commercial sales.
  • As of early 2026, the company held approximately $9 million in cash, a runway sufficient only until the fourth quarter of 2026.
  • The short cash runway implies a high probability of additional financing & potential share dilution for investors.
  • Peer analysis includes Innate Pharma (IPHA), MiNK Therapeutics (INKT), Century Therapeutics (IPSC), & NKGen Biotech (OTC: NKGN).
  • Century Therapeutics holds significantly more capital ($117 million) compared to the tighter balance sheets of GT Biopharma & MiNK Therapeutics.
  • Near-term catalysts include clinical readouts from both trials in late 2026 & resolution of the company's financing needs.
  • The article highlights a valuation gap where the market prices the company at a micro-cap level despite having three clinical-stage assets.
  • The report includes standard disclaimers regarding forward-looking statements, investment risks, & conflicts of interest involving the publisher & its affiliates.